Pharmaceutical Supply – Nirmatrelvir and Ritonavir (Paxlovid)

The contract involves the supply of one box of Pfizer’s Nirmatrelvir and Ritonavir tablets, identified by NDC 00069-5321-30 and commonly known as Paxlovid, for the treatment of COVID-19. This order is governed by federal medical supply chain and defense logistics standards, necessitating strict adherence to procurement protocols, quality control, and distribution requirements applicable to Department of Defense medical resources. The item must be delivered in full compliance with regulatory and logistical frameworks ensuring integrity, traceability, and readiness for deployment in military or federally supported healthcare environments. Issued under the NAICS code 325412 for pharmaceutical preparation manufacturing, the contract was posted on July 13, 2026, with a response deadline of July 16, 2026, and is classified as a subcontract within the Medical Supply Chain Pharm FSA framework managed by the Department of Defense. The place of performance is designated as FPO with ZIP code 96661, indicating delivery to a military postal address, likely for use in overseas or remote service locations. All bidders are expected to meet defense-specific documentation, packaging, and shipping criteria to support timely and secure access to this critical antiviral therapy within the military health system.